Tianjin Sets Up Pharmaceutical Innovation And Technology Transfer Center
This article was originally published in PharmAsia News
Tianjin Institute of Pharmaceutical Research (TIPR), Tianjin Centre for Drug Safety Evaluation and Research, and TIPR Pharmaceutical Responsible Co. Ltd. will jointly set up a pharmaceutical innovation and technology transfer center at the Binhai Hi-Tech Park in Tianjin. The 370-million-yuan ($51.5 million) facility is expected to generate up to 1.5 billion yuan ($208.9 million) of production value for its programs within three years of operation. The center will raise Tianjing city's drug R&D and technical service levels by stimulating beneficial interaction between scientific research and industry. The integration of innovation and technology transfer will greatly spur the development of bioengineering and pharmaceutical industries in the area. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.